Prosecution Insights
Last updated: November 20, 2026

Maria Marvich, USPTO Patent Examiner

Listed by the USPTO as MARVICH, MARIA

Tech Center 1600 • Art Units: 1631 1633 1634 1645

This examiner grants 55% of resolved cases

Analysis

MARVICH, MARIA is assigned to Tech Center 1600 and Art Unit 1631. The profile records 995 resolved cases and an allowance rate of 54.9%. The interview lift is 27.8%, showing a meaningful relationship between interview activity and allowance outcomes within this record, although it remains below the overall allowance rate.

The median time to allowance is 1472 days, so applicants should account for an extended prosecution horizon when setting portfolio expectations. The leading companies are Janssen Pharmaceuticals Inc., Massachusetts Institute of Technology, and Synplogen Co., Ltd. The leading firms are Knobbe, Martens, Olson & Bear, LLP, CANTOR COLBURN LLP, and Johnson, Marcou, Isaacs & Nix, LLC. The large case base supports using these indicators in preparation and workflow planning.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

54.9%
Allow Rate
-5.1% vs TC avg
1,058
Total Applications
+27.8%
Interview Lift
1472
Avg Prosecution Days
Based on 995 resolved cases, 2023–2026

Rejection Statute Breakdown

3.8%
§101 Eligibility
19.0%
§102 Novelty
27.4%
§103 Obviousness
36.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17932633 Modified EC7 Cells Having Low Toxicity to Viral Production Payloads Final Rejection NantBio, Inc.
18545113 ONCOLYTIC VIRUS AND USES THEREOF Non-Final OA Janssen Biotech, Inc.
17813843 COMPOSITIONS AND METHODS FOR DECREASING TAU EXPRESSION Non-Final OA Novartis AG
17839667 MICROFLUIDIC DEVICE FOR ANALYZING GENE EXPRESSION Final Rejection Yeda Research and Development Co. Ltd.
19449304 ENGINEERED MUSCLE TARGETING COMPOSITIONS Non-Final OA Massachusetts Institute of Technology
19355982 ENGINEERED MUSCLE TARGETING COMPOSITIONS Non-Final OA Massachusetts Institute of Technology
17767970 CANINE DISTEMPER VIRUS HEMAGGLUTININ AND FUSION POLYPEPTIDES Final Rejection Mayo Foundation for Medical Education and Research
17768591 COMPOSITIONS AND METHODS FOR USING ALTERNATIVE SPLICING TO CONTROL SPECIFICITY OF GENE THERAPY Final Rejection The Johns Hopkins University
18705359 METHOD FOR PRODUCING MILK LIKE PRODUCTS Non-Final OA SOCIETE DES PRODUITS NESTLE S.A.
19361525 Unique Interferon Alpha 2B And New Method Of Making Thereof Non-Final OA PharmaEssentia Corporation
18019423 Molecular Targets for Modulation of Dissociative and Associative States Final Rejection The Board of Trustees of the Leland Stanford Junior University
18612441 TREATMENT AGENT FOR HAIR DAMAGE Final Rejection TOHOKU UNIVERSITY
17694841 Viral Vectors for Prophylaxis and Therapy of Hemoglobinopathies Non-Final OA The Children's Hospital of Philadelphia
18268533 MICROCARRIER FOR CELL CULTURE AND CELL CULTURE METHOD Non-Final OA SEKISUI CHEMICAL CO., LTD.
18875094 CAR-EXPRESSING PLURIPOTENT STEM CELL-DERIVED NEUTROPHILS LOADED WITH DRUG NANOPARTICLES AND USES THEREOF Non-Final OA Purdue Research Foundation
18031486 Engineered Cells for Increased Collagen Production Non-Final OA Northeastern University
18574777 ENGINEERED NODAVIRAL CARGO DELIVERY SYSTEMS Non-Final OA ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
18051936 MINIATURIZED DYSTROPHINS HAVING SPECTRIN FUSION DOMAINS AND USES THEREOF Non-Final OA BRISTOL-MYERS SQUIBB COMPANY
18847004 DELIVERY METHODS USING PLATELETS Non-Final OA Children's Hospital Medical Center
18701144 INNER EAR ORGANOIDS HAVING IMPROVED HAIR CELL DIFFERENTIATION ABILITY AND METHOD FOR PRODUCING SAME Final Rejection AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
18748156 HYPOVENTILATION PHYSICAL MODELS AND APPLICATIONS THEREOF Non-Final OA The University of Hong Kong
17904229 LINKING AMINO ACID SEQUENCES, MANUFACTURING METHOD THEREOF, AND USE THEREOF Non-Final OA Temple University-Of The Commonwealth System of Higher Education
17050601 THERAPEUTIC GENOME EDITING IN X-LINKED HYPER IGM SYNDROME Final Rejection Seattle Children's Hospital (dba Seattle Children's Research Institute)
18074107 TARGETING BCL11A DISTAL REGULATORY ELEMENTS FOR FETAL HEMOGLOBIN REINDUCTION Non-Final OA The Children's Medical Center Corporation

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Maria Marvich's allowance rate?

54.9% of resolved applications examined by Maria Marvich were allowed (995 resolved cases), compared with 28.0% across Art Unit 1631 over the last five years.

Does an interview help with examiner Maria Marvich?

This examiner's interview lift is +27.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Maria Marvich take to allow a patent?

Applications allowed by Maria Marvich took 1,472 days on average from filing to allowance.

Which art unit does examiner Maria Marvich work in?

Maria Marvich examines applications in Art Unit 1631 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month